Interplay between AP-1 and estrogen receptor α in regulating gene expression and proliferation networks in breast cancer cells

Carcinogenesis

Volumn 33, Issue 9, 2012, Pages 1684-1691

  Dahlman Wright, Karin ^a   Qiao, Yichun ^a   Jonsson, Philip ^b   Gustafsson, Jan Åke ^a,b   Williams, Cecilia ^b   Zhao, Chunyan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F1;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION; MOLECULAR INTERACTION; ONCOGENE C FOS; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; E2F1 TRANSCRIPTION FACTOR; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; TRANSCRIPTION FACTOR AP-1;

EID: 84865556405     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs223     Document Type: Article

References (43)

1. Nilsson, S. et al. (2002) Estrogen receptor action. Crit. Rev. Eukaryot. Gene Expr., 12, 237-257.
2. Klinge, C.M. (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res., 29, 2905-2919.
3. Kushner, P.J. et al. (2000) Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol., 74, 311-317.
4. Saville, B. et al. (2000) Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem., 275, 5379-5387.
5. Shaulian, E. et al. (2002) AP-1 as a regulator of cell life and death. Nat. Cell Biol., 4, E131-E136.
6. Rauscher, F.J. et al. (1988) Fos and Jun bind cooperatively to the AP-1 site: reconstitution in vitro. Genes Dev., 2, 1687-1699.
7. Webb, P. et al. (1999) The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol. Endocrinol., 13, 1672-1685.
8. Umayahara, Y. et al. (1994) Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J. Biol. Chem., 269, 16433-16442.
9. Schmitt, M. et al. (1995) Positive and negative effects of nuclear receptors on transcription activation by AP-1 of the human choline acetyltransferase proximal promoter. J. Neurosci. Res., 40, 152-164.
10. Liu, Y. et al. (2004) AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene, 23, 8238-8246.
11. Lu, C. et al. (2005) cFos is critical for MCF-7 breast cancer cell growth. Oncogene, 24, 6516-6524.
12. Smith, L.M. et al. (1999) cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene, 18, 6063-6070.
13. Johnston, S.R. et al. (1999) Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin. Cancer Res., 5, 251-256.
14. Zhou, Y. et al. (2007) Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer, 7, 59.
15. Wang, W. et al. (1999) Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol. Endocrinol., 13, 1373-1387.
16. Dimova, D.K. et al. (2005) The E2F transcriptional network: old acquaintances with new faces. Oncogene, 24, 2810-2826.
17. Stender, J.D. et al. (2007) Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol. Endocrinol., 21, 2112-2123.
18. Han, S. et al. (2003) E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res. Treat., 82, 11-16.
19. Carroll, J.S. et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat. Genet., 38, 1289-1297.
20. Liu, Y. et al. (2008) The genome landscape of ERalpha- and ERbeta-binding DNA regions. Proc. Natl Acad. Sci. USA, 105, 2604-2609.
21. Subramanian, A. et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA, 102, 15545-15550.
22. Zhao, C. et al. (2007) Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res., 67, 3955-3962.
23. Zhao, C. et al. (2010) Genome-wide mapping of estrogen receptor-beta-binding regions reveals extensive cross-talk with transcription factor activator protein-1. Cancer Res., 70, 5174-5183.
24. Madak-Erdogan, Z. et al. (2011) Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. Mol. Cell Biol., 31, 226-236.
25. Cao, A.R. et al. (2011) Genome-wide analysis of transcription factor E2F1 mutant proteins reveals that N- and C-terminal protein interaction domains do not participate in targeting E2F1 to the human genome. J. Biol. Chem., 286, 11985-11996.
26. Chung, S. et al. (2009) Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. Oncogene, 28, 2849-2859.
27. Ginestier, C. et al. (2006) Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin. Cancer Res., 12, 4533-4544.
28. Gluck, S. et al. (2012) TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res. Treat., 132, 781-791.
29. Julka, P.K. et al. (2008) A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br. J. Cancer, 98, 1327-1335.
30. Kao, K.J. et al. (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer, 11, 143.
31. Korde, L.A. et al. (2010) Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res. Treat., 119, 685-699.
32. Lu, X. et al. (2008) Predicting features of breast cancer with gene expression patterns. Breast Cancer Res. Treat., 108, 191-201.
33. Saal, L.H. et al. (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl Acad. Sci. USA, 104, 7564-7569.
34. Sorlie, T. et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA, 100, 8418-8423.
35. van de Vijver, M.J. et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 347, 1999-2009.
36. Waddell, N. et al. (2010) Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay. J. Pathol., 221, 452-461.
37. Biddie, S.C. et al. (2011) Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. Mol. Cell, 43, 145-155.
38. Shen, Q. et al. (2011) Liver X receptor-retinoid X receptor (LXR-RXR) heterodimer cistrome reveals coordination of LXR and AP1 signaling in keratinocytes. J. Biol. Chem., 286, 14554-14563.
39. Shen, Q. et al. (2008) The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene, 27, 366-377.
40. Wang, A. et al. (2000) Regulation of BRCA1 expression by the Rb-E2F pathway. J. Biol. Chem., 275, 4532-4536.
41. Vuaroqueaux, V. et al. (2007) Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res., 9, R33.
42. Engelmann, D. et al. (2012) The dark side of E2F1: in transit beyond apoptosis. Cancer Res., 72, 571-575.
43. Dalton, G.D. et al. (2006) Protein kinase inhibitor peptide (PKI): a family of endogenous neuropeptides that modulate neuronal cAMP-dependent protein kinase function. Neuropeptides, 40, 23-34.